117 related articles for article (PubMed ID: 37119764)
1. Epigenetic regulation of DHRS2 by SUV420H2 inhibits cell apoptosis in renal cell carcinoma.
Ryu TY; Lee J; Kang Y; Son MY; Kim DS; Lee YS; Kim MY; Cho HS
Biochem Biophys Res Commun; 2023 Jun; 663():41-46. PubMed ID: 37119764
[TBL] [Abstract][Full Text] [Related]
2. miR-29a contributes to breast cancer cells epithelial-mesenchymal transition, migration, and invasion via down-regulating histone H4K20 trimethylation through directly targeting SUV420H2.
Wu Y; Shi W; Tang T; Wang Y; Yin X; Chen Y; Zhang Y; Xing Y; Shen Y; Xia T; Guo C; Pan Y; Jin L
Cell Death Dis; 2019 Feb; 10(3):176. PubMed ID: 30792382
[TBL] [Abstract][Full Text] [Related]
3. SUV420H2 is an epigenetic regulator of epithelial/mesenchymal states in pancreatic cancer.
Viotti M; Wilson C; McCleland M; Koeppen H; Haley B; Jhunjhunwala S; Klijn C; Modrusan Z; Arnott D; Classon M; Stephan JP; Mellman I
J Cell Biol; 2018 Feb; 217(2):763-777. PubMed ID: 29229751
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of the long noncoding RNA TUG1 inhibits the proliferation, migration, invasion and promotes apoptosis of renal cell carcinoma.
Zhang M; Lu W; Huang Y; Shi J; Wu X; Zhang X; Jiang R; Cai Z; Wu S
J Mol Histol; 2016 Aug; 47(4):421-8. PubMed ID: 27323757
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of NSD2 Suppresses Renal Cell Carcinoma Metastasis by Inhibiting Epithelial-Mesenchymal Transition.
Han X; Piao L; Yuan X; Wang L; Liu Z; He X
Int J Med Sci; 2019; 16(10):1404-1411. PubMed ID: 31692936
[No Abstract] [Full Text] [Related]
6. Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer.
Han Y; Wang Z; Sun S; Zhang Z; Liu J; Jin X; Wu P; Ji T; Ding W; Wang B; Gao Q
Epigenetics; 2020; 15(1-2):122-133. PubMed ID: 31423895
[TBL] [Abstract][Full Text] [Related]
7. Lysine methyltransferase 5C increases the proliferation and metastatic abilities of clear cell renal cell carcinoma via aerobic glycolysis.
Zeng B; Wan R; Chang K; Li J; Zhang X; Shi G; Ye D; Xu F
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38426605
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of ALPK2 blocks development and progression of renal cell carcinoma.
Jiang J; Han P; Qian J; Zhang S; Wang S; Cao Q; Shao P
Exp Cell Res; 2020 Jul; 392(2):112029. PubMed ID: 32330508
[TBL] [Abstract][Full Text] [Related]
9. siRNA Suppression of NEDD9 Inhibits Proliferation and Enhances Apoptosis in Renal Cell Carcinoma.
Wang J; Yang WJ; Sun C; Luan Y; Cheng GH; Li KL; Kong F
Oncol Res; 2014; 22(4):219-224. PubMed ID: 26351211
[TBL] [Abstract][Full Text] [Related]
10. UHRF1 promotes renal cell carcinoma progression through epigenetic regulation of TXNIP.
Jiao D; Huan Y; Zheng J; Wei M; Zheng G; Han D; Wu J; Xi W; Wei F; Yang AG; Qin W; Wang H; Wen W
Oncogene; 2019 Jul; 38(28):5686-5699. PubMed ID: 31043707
[TBL] [Abstract][Full Text] [Related]
11. Histone H4 Methyltransferase Suv420h2 Maintains Fidelity of Osteoblast Differentiation.
Khani F; Thaler R; Paradise CR; Deyle DR; Kruijthof-de Julio M; Galindo M; Gordon JA; Stein GS; Dudakovic A; van Wijnen AJ
J Cell Biochem; 2017 May; 118(5):1262-1272. PubMed ID: 27862226
[TBL] [Abstract][Full Text] [Related]
12. miR‑539 suppresses proliferation and induces apoptosis in renal cell carcinoma by targeting high mobility group A2.
Ye ZH; Gui DW
Mol Med Rep; 2018 Apr; 17(4):5611-5618. PubMed ID: 29436648
[TBL] [Abstract][Full Text] [Related]
13. Cyanidin Curtails Renal Cell Carcinoma Tumorigenesis.
Liu X; Zhang D; Hao Y; Liu Q; Wu Y; Liu X; Luo J; Zhou T; Sun B; Luo X; Xu J; Wang Q; Yang Z; Li L
Cell Physiol Biochem; 2018; 46(6):2517-2531. PubMed ID: 29742507
[TBL] [Abstract][Full Text] [Related]
14. miR-1293 Suppresses Tumor Malignancy by Targeting Hydrocyanic Oxidase 2: Therapeutic Potential of a miR-1293/Hydrocyanic Oxidase 2 Axis in Renal Cell Carcinoma.
Liu XL; Pan WG; Li KL; Mao YJ; Liu SD; Zhang RM
Cancer Biother Radiopharm; 2020 Jun; 35(5):377-386. PubMed ID: 31971830
[TBL] [Abstract][Full Text] [Related]
15. Non-coding RNA 886 promotes renal cell carcinoma growth and metastasis through the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
Lei J; Xiao JH; Zhang SH; Liu ZQ; Huang K; Luo ZP; Xiao XL; Hong ZD
Mol Med Rep; 2017 Oct; 16(4):4273-4278. PubMed ID: 28765891
[TBL] [Abstract][Full Text] [Related]
16. HDAC1-induced epigenetic silencing of ASPP2 promotes cell motility, tumour growth and drug resistance in renal cell carcinoma.
Li H; Wang X; Zhang C; Cheng Y; Yu M; Zhao K; Ge W; Cai A; Zhang Y; Han F; Hu Y
Cancer Lett; 2018 Sep; 432():121-131. PubMed ID: 29890207
[TBL] [Abstract][Full Text] [Related]
17. Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-β activation.
Yu CP; Ho JY; Huang YT; Cha TL; Sun GH; Yu DS; Chang FW; Chen SP; Hsu RJ
PLoS One; 2013; 8(2):e56667. PubMed ID: 23460808
[TBL] [Abstract][Full Text] [Related]
18. VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.
Liu C; Liu L; Wang K; Li XF; Ge LY; Ma RZ; Fan YD; Li LC; Liu ZF; Qiu M; Hao YC; Shi ZF; Xia CY; Strååt K; Huang Y; Ma LL; Xu D
Oncogene; 2020 May; 39(21):4286-4298. PubMed ID: 32291411
[TBL] [Abstract][Full Text] [Related]
19. DHRS2 mediates cell growth inhibition induced by Trichothecin in nasopharyngeal carcinoma.
Luo X; Li N; Zhao X; Liao C; Ye R; Cheng C; Xu Z; Quan J; Liu J; Cao Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):300. PubMed ID: 31291971
[TBL] [Abstract][Full Text] [Related]
20.
Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
